Characteristics of patients experiencing relapse
| Characteristic . | N (%) . | ||
|---|---|---|---|
| All (n = 16) . | PET− (n = 13) . | PET+ (n = 3) . | |
| Age, y | |||
| 50+ | 1 (6) | 1 (8) | 0 |
| Stage | |||
| IB | 1 (6) | 0 | 1 (33) |
| IIA | 10 (63) | 8 (61) | 2 (67) |
| IIB | 4 (25) | 4 (31) | 0 |
| Not reported/unknown | 1 (6) | 1 (8) | 0 |
| ESR | |||
| 50+ | 5 (31) | 4 (31) | 1 (33) |
| GHSG | |||
| Favorable | 8 (50) | 7 (54) | 1 (33) |
| Unfavorable | 8 (50) | 6 (46) | 2 (67) |
| EORTC/LYSA/FIL | |||
| Favorable | 8 (50) | 7 (54) | 1 (33) |
| Unfavorable | 8 (50) | 6 (46) | 2 (67) |
| Sites of relapse* | |||
| R supraclavicular | 3 (19) | 3 (23) | 0 |
| L supraclavicular | 2 (13) | 1 (8) | 1 (33) |
| R axilla | 1 (6) | 1 (8) | 0 |
| L axilla | 1 (6) | 1 (8) | 0 |
| Mediastinal | 5 (31) | 3 (23) | 2 (67) |
| Spleen | 1 (6) | 1 (8) | 0 |
| Paraaortic | 1 (6) | 1 (8) | 0 |
| Unknown | 2 (13) | 2 (15) | 0 |
| Characteristic . | N (%) . | ||
|---|---|---|---|
| All (n = 16) . | PET− (n = 13) . | PET+ (n = 3) . | |
| Age, y | |||
| 50+ | 1 (6) | 1 (8) | 0 |
| Stage | |||
| IB | 1 (6) | 0 | 1 (33) |
| IIA | 10 (63) | 8 (61) | 2 (67) |
| IIB | 4 (25) | 4 (31) | 0 |
| Not reported/unknown | 1 (6) | 1 (8) | 0 |
| ESR | |||
| 50+ | 5 (31) | 4 (31) | 1 (33) |
| GHSG | |||
| Favorable | 8 (50) | 7 (54) | 1 (33) |
| Unfavorable | 8 (50) | 6 (46) | 2 (67) |
| EORTC/LYSA/FIL | |||
| Favorable | 8 (50) | 7 (54) | 1 (33) |
| Unfavorable | 8 (50) | 6 (46) | 2 (67) |
| Sites of relapse* | |||
| R supraclavicular | 3 (19) | 3 (23) | 0 |
| L supraclavicular | 2 (13) | 1 (8) | 1 (33) |
| R axilla | 1 (6) | 1 (8) | 0 |
| L axilla | 1 (6) | 1 (8) | 0 |
| Mediastinal | 5 (31) | 3 (23) | 2 (67) |
| Spleen | 1 (6) | 1 (8) | 0 |
| Paraaortic | 1 (6) | 1 (8) | 0 |
| Unknown | 2 (13) | 2 (15) | 0 |
ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; ESR, erythrocyte sedimentation rate; FIL, Fondazione Italiana Linfomi; GHSG, German Hodgkin Study Group; L, left; LYSA, Lymphoma Study Association; R, right.
New sites occurred in 3 PET− patients (L axilla, spleen, paraaortic).